company background image
PBYI logo

Puma Biotechnology NasdaqGS:PBYI Stock Report

Last Price

US$4.02

Market Cap

US$193.0m

7D

-3.6%

1Y

22.9%

Updated

28 May, 2024

Data

Company Financials +

Puma Biotechnology, Inc.

NasdaqGS:PBYI Stock Report

Market Cap: US$193.0m

PBYI Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

PBYI fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

Puma Biotechnology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Puma Biotechnology
Historical stock prices
Current Share PriceUS$4.02
52 Week HighUS$7.73
52 Week LowUS$2.13
Beta1.3
1 Month Change-19.92%
3 Month Change-39.09%
1 Year Change22.94%
3 Year Change-62.47%
5 Year Change-73.06%
Change since IPO-70.22%

Recent News & Updates

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Recent updates

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Aug 04

Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Jun 04
Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Puma Bio: Still Worthy Of Consideration After Earnings Surprise

Mar 08

Shareholder Returns

PBYIUS BiotechsUS Market
7D-3.6%-1.9%-0.3%
1Y22.9%7.4%25.6%

Return vs Industry: PBYI exceeded the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: PBYI matched the US Market which returned 25.6% over the past year.

Price Volatility

Is PBYI's price volatile compared to industry and market?
PBYI volatility
PBYI Average Weekly Movement10.0%
Biotechs Industry Average Movement11.2%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: PBYI's share price has been volatile over the past 3 months.

Volatility Over Time: PBYI's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010185Alan Auerbachwww.pumabiotechnology.com

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.

Puma Biotechnology, Inc. Fundamentals Summary

How do Puma Biotechnology's earnings and revenue compare to its market cap?
PBYI fundamental statistics
Market capUS$192.96m
Earnings (TTM)US$15.38m
Revenue (TTM)US$226.63m

12.6x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PBYI income statement (TTM)
RevenueUS$226.63m
Cost of RevenueUS$60.19m
Gross ProfitUS$166.44m
Other ExpensesUS$151.06m
EarningsUS$15.38m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.32
Gross Margin73.44%
Net Profit Margin6.78%
Debt/Equity Ratio196.2%

How did PBYI perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.